Investigational drug · Phase 2
LY03015
Also called: LPM3770164 sustained release
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tardive Dyskinesia (TD).
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "LY03015"
First trial start
2025
Jan 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY03015", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tardive Dyskinesia (TD)
Approved drugs for the same conditions: Tardive dyskinesia · Neurology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "LY03015" as an intervention, largest first.
- Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaPivotal-lookingRecruiting
Luye Pharma Group Ltd.Industry
NCT06731868 · 120 participants (planned) · Start Jan 14, 2025 · Primary completion Oct 31, 2025
Drug: LPM3770164 sustained release tablet 5 mg; LPM3770164 sustained release tablet 10 mg and 2 more · For: Tardive Dyskinesia (TD)
Sites: Shanghai, China
- A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsPivotal-lookingCompleted
Luye Pharma Group Ltd.Industry
NCT05238701 · 104 participants · Start Feb 25, 2022 · Primary completion Nov 4, 2023
Drug: LPM3770164 sustained release tablet; LPM3770164 sustained release tablet simulant · For: Huntington Disease; Tardive Dyskinesia
Sites: Shanghai, China
Luye Pharma Group Ltd.Industry
NCT07671833 · 24 participants · Start Apr 15, 2026 · Primary completion May 8, 2026
Drug: LY03015 (LPM3770164 extended-release tablets) · For: Healthy Participants
Sites: Los Alamitos, California
Luye Pharma Group Ltd.Industry
NCT06474650 · 16 participants · Start Jul 31, 2024 · Primary completion Sep 25, 2024
Drug: LPM3770164 sustained release tablet · For: Huntington Disease; Tardive Dyskinesia
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.